OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC jointly filed a Form 4 with the SEC on November 18, 2026, disclosing multiple changes in beneficial ownership of Windward Bio Group AG common shares on November 16, 2026, in connection with the issuer's initial public offering.

Key Highlights

  • IPO purchase: OrbiMed Advisors acquired 1,176,471 common shares at $17.00 per share in Windward Bio Group AG's initial public offering on November 16, 2026.
  • Preferred share conversions: 3,561,936 Series A Preferred Shares and 1,611,008 Series B Preferred Shares each automatically converted into common shares on a 1-to-1 basis immediately prior to the IPO closing.
  • Warrant exercise: 216,668 warrants were exercised (transaction code M) at an exercise price of $0.02, with the warrants described as fully vested and exercisable, and an expiration date of May 12, 2036.
  • Shares withheld: 232 common shares were withheld (transaction code F) at $17.00 per share in connection with the warrant exercise.
  • Resulting ownership: Following all reported transactions, OrbiMed Advisors reported indirect beneficial ownership of 7,097,483 common shares of Windward Bio Group AG.
  • Board representation: According to the filing, the reporting persons designated David P. Bonita, a member of OrbiMed Advisors, to serve on Windward Bio Group AG's board of directors.
  • Dual roles: Both reporting persons are identified as Director and 10% Owner of Windward Bio Group AG (NASDAQ:WWB).

OrbiMed's Ownership Changes in Windward Bio Group Following IPO

According to the filing, all reported transactions occurred on November 16, 2026, and are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC serves as the general partner of OPI IX, and OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP IX LLC. The filing states that by virtue of these relationships, both entities "may be deemed to have voting and investment power with respect to the securities held by OPI IX." OrbiMed Advisors exercises this power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom, the filing notes, disclaims beneficial ownership of the shares held by OPI IX.

The filing discloses that the 1,176,471 common shares acquired under transaction code P reflect shares purchased in the issuer's initial public offering at $17.00 per share. The Series A and Series B Preferred Share conversions (transaction code C) each occurred on a 1-to-1 basis and are described as having no expiration date. The warrant exercise price of $0.02 is stated in U.S. dollars and, according to the filing, "reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors."

The filing further notes that each reporting person "disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except to the extent of its pecuniary interest therein, if any," and states that the report "shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose." The form was signed by Carl L. Gordon on behalf of both OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC.

What Was Disclosed

OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC jointly reported five transactions in Windward Bio Group AG common shares on November 16, 2026, resulting in indirect beneficial ownership of 7,097,483 common shares following the issuer's initial public offering.